Oracle Develops Cloud System to Support Covid-19 Vaccine Trials
16 Julio 2020 - 5:21PM
Noticias Dow Jones
By Stephen Nakrosis
Oracle Corp. on Thursday said it was working with the National
Institute of Allergy and Infectious Diseases, part of the U.S.
National Institutes of Health, to "developed a Cloud System called
the CoVPN Volunteer Screening Registry to identify and screen
volunteers who want to participate in COVID-19 clinical
trials."
The company also said the system has been seen over 100,000
people already registered, despite the fact it has been live for
less than a week.
The new system is part of the recently established Covid-19
Prevention Network, which aims to "register millions of volunteers
for large-scale clinical testing of vaccines and monoclonal
antibodies intended to protect people from Covid-19," the company
said. "This program is expected to support hundreds of clinical
trial sites across the United States and internationally by the end
of the year."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 16, 2020 18:06 ET (22:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Oracle (NYSE:ORCL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Oracle (NYSE:ORCL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
